ASCO 2024

Article collection

We are proud to present a special collection of articles for the American Society of Clinical Oncology Annual Meeting 2024. This curated selection showcases the cutting-edge advancements and novel perspectives published in journals from Elsevier's Oncology Journal Network. We invite you to explore this collection and delve deeper into the exciting advancements shaping the future of cancer research.

Annals of Oncology

• ●

  Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040opens in new tab/window

• ●

  Timing of Radiotherapy (RT) After Radical Prostatectomy (RP): Long-term outcomes in the RADICALS-RT trial [NCT00541047]opens in new tab/window

Blood Neoplasia

• ●

  Patients with Castleman disease report mild COVID-19 symptoms and mount a humoral response to SARS-CoV-2 vaccinationopens in new tab/window

Cancer Epidemiology

• ●

  Risk factors for early-onset colorectal cancer: A Canadian prospective cohort studyopens in new tab/window

• ●

  Metformin’s role in lowering colorectal cancer risk among individuals with diabetes from the Southern Community Cohort Studyopens in new tab/window

Cancer Letters

• ●

  Organoid: Bridging the gap between basic research and clinical practiceopens in new tab/window

• ●

  SPOP-mutant prostate cancer: Translating fundamental biology into patient careopens in new tab/window

Cancer Pathogenesis and Therapy

• ●

  PI3K/AKT/mTOR pathway, hypoxia, and glucose metabolism: Potential targets to overcome radioresistance in small cell lung canceropens in new tab/window

• ●

  Distinct T helper cell-mediated antitumor immunity: T helper 2 cells in focusopens in new tab/window

• ●

  Clinical characteristics and treatment outcomes of Chinese diffuse large B-cell lymphoma patients in the era of rituximab (2005–2018)opens in new tab/window

Cancer Treatment Reviews

• ●

  Waiting for the “liquid revolution” in the adjuvant treatment of colon cancer patients: a review of ongoing trialsopens in new tab/window

• ●

  First-line combination treatment with PARP and androgen receptor–signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United Statesopens in new tab/window

Clinical Breast Cancer

• ●

  Unlocking the Power of the Homing Phenomenon: Why Breast Conserving Surgery Outshines Mastectomy in Overall Survivalopens in new tab/window

• ●

  Robotics in Screening, Diagnosis and Treatment of Breast Cancer: A Perspective Viewopens in new tab/window

• ●

  Risk of Recurrence in Patients With HER2+ Early-Stage Breast Cancer: Literature Analysis of Patient and Disease Characteristicsopens in new tab/window

Clinical Colorectal Cancer

• ●

  Adjuvant Chemotherapy for Older Patients With Stage III Colorectal Cancer: A Real-World Analysis of Treatment Recommendations, Treatment Administered and Impact on Cancer Recurrenceopens in new tab/window

• ●

  Consideration of Metastasis-Directed Therapy for Patients With Metastatic Colorectal Cancer: Expert Survey and Systematic Reviewopens in new tab/window

• ●

  A Case of Heavily Pretreated HER2+ Colorectal Liver Metastases Responsive to Hepatic Arterial Infusion Chemotherapyopens in new tab/window

Clinical Genitourinary Cancer

• ●

  Combined Cabazitaxel and Carboplatin Treatment of Metastatic Castration Resistant Prostate Cancer Patients, With Innate or Acquired Resistance to Cabazitaxel Monotherapyopens in new tab/window

• ●

  Cystic Pelvic Masses in Men: A Presentation of Uncommon Cases and a Literature Reviewopens in new tab/window

• ●

  The Impact of Blue Light Cystoscopy Use Among Nonmuscle Invasive Bladder Cancer Patients in an Equal Access Setting: Implications on Recurrence and Time to Recurrenceopens in new tab/window

Clinical Lung Cancer

• ●

  Lung Cancer in Women: The Past, Present, and Futureopens in new tab/window

• ●

  Perioperative Immunotherapy for Non-Small Cell Lung Cancer: Practical Application of Emerging Data and New Challengesopens in new tab/window

• ●

  Personalised Assessment and Rapid Intervention in Frail Patients With Lung Cancer: The Impact of an Outpatient Occupational Therapy Serviceopens in new tab/window

Clinical Lymphoma Myeloma and Leukemia

• ●

  Recommendations for Management of Secondary Antibody Deficiency in Multiple Myelomaopens in new tab/window

• ●

  Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trialopens in new tab/window

• ●

  Optimizing the CAR T-Cell Therapy Experience in Multiple Myeloma: Clinical Pearls From an Expert Roundtableopens in new tab/window

Clinics

• ●

  Delayed diagnosis and increased mortality risk: Assessing the effects of the COVID-19 pandemic on breast cancer recurrenceopens in new tab/window

• ●

  Health-Related quality of life by 31-item Cervantes scale in breast cancer survivors undergoing adjuvant endocrine therapyopens in new tab/window

• ●

  Prolonged survival after thoracic metastasectomy in patients with nonseminomatous testicular canceropens in new tab/window

Critical Reviews in Oncology/Hematology

• ●

  A practical algorithm for acute myeloid leukaemia diagnosis following the updated 2022 classificationsopens in new tab/window

• ●

  Oncogenic fusions: Targeting NTRKopens in new tab/window

• ●

  Unraveling molecular signatures in rare bone tumors and navigating the cancer pathway landscapes for targeted therapeuticsopens in new tab/window

ESMO Gastrointestinal Oncology

• ●

  Benefits from early trial involvement in metastatic colorectal cancer: outcomes from the phase I unit at the Sarah Cannon Research Institute UKopens in new tab/window

• ●

  Exploring the differences in the tumor microenvironment and immuno-oncologic targets in pancreatic ductal adenocarcinomas (PDAC) according to KRAS mutational statusopens in new tab/window

ESMO Open

• ●

  Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trialopens in new tab/window

• ●

  Antibody–drug conjugates are active in patients with HER2-positive breast cancer brain metastases: where do we go from here?opens in new tab/window

ESMO Real World Data and Digital Oncology

• ●

  Toward optimizing patient selection for EGFR antibody therapies in metastatic colorectal cancer: outcomes and resistance features in real-world dataopens in new tab/window

• ●

  Real-world patterns of treatment and response in metastatic renal cell carcinoma: a multicentre UK-wide review with UK Renal Oncology Collaborative (UK ROC)opens in new tab/window

Gynecologic Oncology

• ●

  Enhanced recovery after surgery (ERAS®) society guidelines for gynecologic oncology: Addressing implementation challenges - 2023 updateopens in new tab/window

• ●

  Associations of metformin therapy treatment with endometrial cancer risk and prognosis: A systematic review and meta-analysisopens in new tab/window

• ●

  Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian canceropens in new tab/window

• ●

  A personalized probabilistic approach to ovarian cancer diagnosticsopens in new tab/window

Gynecologic Oncology Reports

• ●

  Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansineopens in new tab/window

• ●

  The challenging journey of cervical cancer diagnosis and treatment at the second largest hospital in Indonesiaopens in new tab/window

• ●

  Quality corner: Safely using cephalosporins in almost all patients with penicillin allergies: Mini-review and suggested protocol to improve efficacy and surgical outcomesopens in new tab/window

• ●

  Ovarian cancer think tank: An overview of the current status of ovarian cancer screening and recommendations for future directionsopens in new tab/window

Immuno-Oncology and Technology

• ●

  Immune biomarker evaluation of sequential tyrosine kinase inhibitor and nivolumab monotherapies in renal cell carcinoma: The phase 1 TRIBE trialopens in new tab/window

• ●

  Engineering approaches for innate immune-mediated tumor microenvironment remodelingopens in new tab/window

Journal of Cancer Policy

• ●

  Implications of FDA’s marketing authorization of hereditary cancer testingopens in new tab/window

• ●

  INDIGO: Example of inappropriate crossover and why PFS cannot be the primary outcome in gliomasopens in new tab/window

Journal of the National Cancer Center

• ●

  Cancer incidence and mortality in China, 2016opens in new tab/window

• ●

  Patterns and trends in esophageal cancer incidence and mortality in China: An analysis based on cancer registry dataopens in new tab/window

• ●

  The roles of histone modifications in tumorigenesis and associated inhibitors in cancer therapyopens in new tab/window

Journal of Thoracic Oncology

• ●

  Read here for the Journal of Thoracic Oncology ASCO articles.opens in new tab/window

Leukemia Research

• ●

  CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123opens in new tab/window

• ●

  Identification of unique molecular heterogeneity of human CD79, the signaling component of the human B cell antigen receptor (BCR), and synergistic potentiation of the CD79-targeted therapy of B cell tumors by co-targeting of CD79a and CD79bopens in new tab/window

• ●

  The clinical, molecular, and prognostic features of the 2022 WHO and ICC classification systems for myelodysplastic neoplasmsopens in new tab/window

Leukemia Research Reports

• ●

  Successful anti-tumor effects with two novel bifunctional chemotherapeutic compounds that combine a LAT1 substrate with cytotoxic moieties in aggressive T-cell lymphomasopens in new tab/window

• ●

  Myeloid neoplasms in inflammatory bowel disease: A case series and review of the literatureopens in new tab/window

• ●

  Long-term follow-up of efficacy and safety in elderly patients with chronic myeloid leukemia treated with intermittent low dose dasatinib therapyopens in new tab/window

Magnetic Resonance Imaging

• ●

  Delineation of the internal iliac vein using MRI with true FISP sequence in patients with locally recurrent rectal cancer: A pilot study using CT/MRI fusionopens in new tab/window

Neoplasia

• ●

  Interdisciplinary care of children with diffuse midline gliomaopens in new tab/window

Oral Oncology

• ●

  HER2-targeted therapies for salivary gland cancersopens in new tab/window

• ●

  Longitudinal post-radiotherapy plasma Epstein-Barr virus DNA trends inform on optimal risk stratification in endemic nasopharyngeal carcinomaopens in new tab/window

Oral Oncology Reports

• ●

  Salivary exosomes as biomarkers for early diagnosis of oral squamous cell carcinomaopens in new tab/window

Radiation Medicine and Protection

• ●

  Comparison of pencil beam and Monte Carlo calculations with ion chamber array measurements for patient-specific quality assuranceopens in new tab/window

• ●

  Alzheimer's disease and low-dose radiation therapy: A new hopeopens in new tab/window

• ●

  Expert consensus on radiotherapy combined with immunotherapy for esophageal cancer (2024 edition)opens in new tab/window

Seminars in Oncology

• ●

  PARP inhibitors: A review of the pharmacology, pharmacokinetics, and pharmacogeneticsopens in new tab/window

• ●

  PARP inhibitors for prostate canceropens in new tab/window

Surgical Oncology Insight

• ●

  The effect of the pandemic on colorectal cancer in the United States: an increased disease burdenopens in new tab/window

• ●

  Assessing the OPRA Trial for surgical oncologists: Safety and feasibility of a total neoadjuvant therapy approach in patients with rectal canceropens in new tab/window

• ●

  Malignant Bowel Obstruction: Historical Lessons, Current Trends, and Future Directionsopens in new tab/window

• ●

  Implementation of the 2015 American Thyroid Association Guideline Changes Across a Health System: A Quality Improvement Opportunityopens in new tab/window

The Breast

• ●

  Platinum chemotherapy for early triple-negative breast canceropens in new tab/window

• ●

  Effectiveness of hybrid digital breast tomosynthesis/digital mammography compared to digital mammography in women presenting for routine screening at Maroondah BreastScreen: Study protocol for a co-designed, non-randomised prospective trialopens in new tab/window

• ●

  Diagnostic delays in breast cancer among young women: An emphasis on healthcare providersopens in new tab/window

The Journal of Liquid Biopsy

• ●

  Technical evaluation of a novel digital PCR platform for detecting EGFR/KRAS mutations in NSCLC archived plasma specimensopens in new tab/window

• ●

  Liquid biopsy: Cell-free DNA based analysis in breast canceropens in new tab/window

• ●

  New perspectives on inoperable early-stage lung cancer management: Clinicians, physicists, and biologists unveil strategies and insightsopens in new tab/window

ESMO Podcasts

Listen to the most recent podcasts from the ESMO portfolio.

🎙️ ADCs in HER2+ metastatic breast cancer brain metastases - ESMO Podcastsopens in new tab/window

🎙️ Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer by ESMO Podcasts (soundcloud.com)opens in new tab/window

Oncology journal network

We’ll help you find the right home for your research – fast

Publishing your work can be time-consuming, especially if the first journal you submit to isn’t right for your research. With over 40 journals, including The Lancet Oncology, Cancer Cell, European Journal of Cancer and Cancer Letters,  Elsevier’s Oncology Journal Network has the right home for your research. And with our transfer service, you’ll benefit from a smooth, simple publishing process.